San Diego, CA-based Ionian Technologies, Inc. has received additional funding from the Bill & Melinda Gates Foundation to continue to develop a rapid point-of-care diagnostics platform for use in poorer countries.
The grant will extend its total commitment to this program, which was initiated in November 2008, to $3m over two years.
The program will continue to focus on utilizing Ionian’s proprietary isothermal nucleic acid amplification technology, the NEAR Assay, to develop a platform for various global health diseases that will uniquely meet the needs of diagnostics for use in the developing world.
The initial diseases that will be targeted are tuberculosis, chlamydia, and gonorrhea. However, the platform will be easily adapted to other priority global health diseases in subsequent efforts.
Founded in 2000, Ionian Technologies, Inc. is focused on commercializing its proprietary technology for the rapid detection of nucleic acids in various fields, including human in vitro diagnostics, food safety, biodefense, agriculture, and veterinary applications.